West Pharma Is Maintained at Buy by B of A Securities
West Pharma Initiated at Peer Perform by Wolfe Research
BofA Securities Maintains West Pharmaceutical Services(WST.US) With Buy Rating, Announces Target Price $355
Wolfe Research Initiates West Pharmaceutical Services(WST.US) With Hold Rating
West Pharma Raised to Buy From Neutral by UBS
West Pharmaceutical Servs Analyst Ratings
UBS Initiates West Pharmaceutical Services(WST.US) With Buy Rating, Announces Target Price $390
Jefferies Maintains West Pharmaceutical Services(WST.US) With Buy Rating, Maintains Target Price $393
Jefferies Sticks to Their Buy Rating for West Pharmaceutical Services (WST)
BofA Securities Maintains West Pharmaceutical Services(WST.US) With Buy Rating
Jefferies Maintains West Pharmaceutical Services(WST.US) With Buy Rating, Raises Target Price to $393
Stephens Adjusts Price Target on West Pharmaceutical Services to $380 From $340
Jefferies Keeps Their Buy Rating on West Pharmaceutical Services (WST)
DBS Maintains West Pharmaceutical Services(WST.US) With Buy Rating
DBS Maintains West Pharmaceutical Services(WST.US) With Buy Rating
Analysts Offer Insights on Healthcare Companies: West Pharmaceutical Services (WST) and HCA Healthcare (HCA)
Jefferies Adjusts Price Target on West Pharmaceutical Services to $345 From $426
Jefferies Maintains West Pharmaceutical Services(WST.US) With Buy Rating, Cuts Target Price to $345
Stephens Adjusts Price Target on West Pharmaceutical Services to $340 From $400
Hold Rating on West Pharmaceutical Services Amid Forecast Challenges and Demand Slowdown